|  Help  |  About  |  Contact Us

Publication : CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.

First Author  Zhang H Year  2020
Journal  Cancer Cell Volume  37
Issue  1 Pages  37-54.e9
PubMed ID  31883968 Mgi Jnum  J:283653
Mgi Id  MGI:6386861 Doi  10.1016/j.ccell.2019.11.003
Citation  Zhang H, et al. (2020) CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer. Cancer Cell 37(1):37-54.e9
abstractText  Cyclin-dependent kinase 7 (CDK7) is a central regulator of the cell cycle and gene transcription. However, little is known about its impact on genomic instability and cancer immunity. Using a selective CDK7 inhibitor, YKL-5-124, we demonstrated that CDK7 inhibition predominately disrupts cell-cycle progression and induces DNA replication stress and genome instability in small cell lung cancer (SCLC) while simultaneously triggering immune-response signaling. These tumor-intrinsic events provoke a robust immune surveillance program elicited by T cells, which is further enhanced by the addition of immune-checkpoint blockade. Combining YKL-5-124 with anti-PD-1 offers significant survival benefit in multiple highly aggressive murine models of SCLC, providing a rationale for new combination regimens consisting of CDK7 inhibitors and immunotherapies.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

13 Bio Entities

Trail: Publication

0 Expression